201 related articles for article (PubMed ID: 17927643)
1. Disability in chronic migraine with medication overuse: treatment effects at 3 years.
Andrasik F; Grazzi L; Usai S; D'Amico D; Kass S; Bussone G
Headache; 2007 Oct; 47(9):1277-81. PubMed ID: 17927643
[TBL] [Abstract][Full Text] [Related]
2. Disability in chronic migraine with medication overuse: treatment effects through 5 years.
Andrasik F; Grazzi L; Usai S; Kass S; Bussone G
Cephalalgia; 2010 May; 30(5):610-4. PubMed ID: 19614686
[TBL] [Abstract][Full Text] [Related]
3. Chronic migraine with medication overuse: treatment outcome and disability at 3 years follow-up.
Usai S; Grazzi L; Andrasik F; D'Amico D; Rigamonti A; Bussone G
Neurol Sci; 2004 Oct; 25 Suppl 3():S272-3. PubMed ID: 15549557
[TBL] [Abstract][Full Text] [Related]
4. Disability in chronic migraine patients with medication overuse: treatment effects at 1-year follow-up.
Grazzi L; Andrasik F; D'Amico D; Usai S; Kass S; Bussone G
Headache; 2004; 44(7):678-83. PubMed ID: 15209690
[TBL] [Abstract][Full Text] [Related]
5. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.
Bigal ME; Rapoport AM; Sheftell FD; Tepper SJ; Lipton RB
Cephalalgia; 2004 Jun; 24(6):483-90. PubMed ID: 15154858
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
7. Decision-making deficit in chronic migraine patients with medication overuse.
Biagianti B; Grazzi L; Gambini O; Usai S; Muffatti R; Scarone S; Bussone G
Neurol Sci; 2012 May; 33 Suppl 1():S151-5. PubMed ID: 22644192
[TBL] [Abstract][Full Text] [Related]
8. A 3-month analysis of disability, quality of life, and disease course in patients with migraine.
Raggi A; Leonardi M; Bussone G; D'Amico D
Headache; 2013 Feb; 53(2):297-309. PubMed ID: 23094760
[TBL] [Abstract][Full Text] [Related]
9. Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura.
D'Amico D; Grazzi L; Usai S; Rigamonti A; Curone M; Bussone G
Headache; 2005 May; 45(5):553-60. PubMed ID: 15953274
[TBL] [Abstract][Full Text] [Related]
10. Duration of migraine is a predictor for response to botulinum toxin type A.
Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
[TBL] [Abstract][Full Text] [Related]
11. Chronic daily headache in adolescents: an 8-year follow-up study.
Wang SJ; Fuh JL; Lu SR
Neurology; 2009 Aug; 73(6):416-22. PubMed ID: 19605771
[TBL] [Abstract][Full Text] [Related]
12. Endocrine function is altered in chronic migraine patients with medication-overuse.
Rainero I; Ferrero M; Rubino E; Valfrè W; Pellegrino M; Arvat E; Giordano R; Ghigo E; Limone P; Pinessi L
Headache; 2006 Apr; 46(4):597-603. PubMed ID: 16643554
[TBL] [Abstract][Full Text] [Related]
13. Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up.
Zidverc-Trajkovic J; Pekmezovic T; Jovanovic Z; Pavlovic A; Mijajlovic M; Radojicic A; Sternic N
Cephalalgia; 2007 Nov; 27(11):1219-25. PubMed ID: 17888081
[TBL] [Abstract][Full Text] [Related]
14. The impact of intensive patient education on clinical outcome in a clinic-based migraine population.
Rothrock JF; Parada VA; Sims C; Key K; Walters NS; Zweifler RM
Headache; 2006 May; 46(5):726-31. PubMed ID: 16643574
[TBL] [Abstract][Full Text] [Related]
15. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
Freitag FG; Diamond S; Diamond M; Urban G
Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
[TBL] [Abstract][Full Text] [Related]
16. Functional-MRI evaluation of pain processing in chronic migraine with medication overuse.
Chiapparini L; Grazzi L; Ferraro S; Mandelli ML; Usai S; Andrasik F; Bruzzone MG; Bussone G
Neurol Sci; 2009 May; 30 Suppl 1():S71-4. PubMed ID: 19415430
[TBL] [Abstract][Full Text] [Related]
17. Headache prophylaxis with BoNTA: patient characteristics.
Silberstein SD; Marmura MJ; Shaw J; Yu S
Headache; 2010 Jan; 50(1):63-70. PubMed ID: 19549156
[TBL] [Abstract][Full Text] [Related]
18. Similarities and differences between chronic migraine and episodic migraine.
Ferrari A; Leone S; Vergoni AV; Bertolini A; Sances G; Coccia CP; Ottani A; Pinetti D; Sternieri E
Headache; 2007 Jan; 47(1):65-72. PubMed ID: 17355496
[TBL] [Abstract][Full Text] [Related]
19. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
[TBL] [Abstract][Full Text] [Related]
20. HIT-6 and MIDAS as measures of headache disability in a headache referral population.
Sauro KM; Rose MS; Becker WJ; Christie SN; Giammarco R; Mackie GF; Eloff AG; Gawel MJ
Headache; 2010 Mar; 50(3):383-95. PubMed ID: 19817883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
